Our Laboratory
Biomarker and genomic testing for research partners
Our New Haven laboratory supports research and biopharmaceutical partners with microRNA profiling, APOE genotyping, and protein biomarker analyses. The laboratory is CLIA-certified and CAP-accredited and holds a New York State clinical laboratory permit, a Connecticut clinical laboratory license, and permits or licenses in Maryland, California, and Pennsylvania.
Our collaborative services
Biomarker profiling
Biomarker profiling for clinical trials, including sample logistics and data delivery.
APOE genotyping
APOE genotyping for study eligibility, stratification, and translational research.
Custom microRNA assays
Custom microRNA assay development using our validated RT-qPCR workflow.
Integrated testing
Combined genetic, protein, and microRNA testing from a single sample set.
Explore biomarker targets
- Amyloid-β 42/40 ratio (Aβ42/Aβ40) – a lower ratio reflects brain amyloid deposition; the classic CSF marker, now measured in plasma
- Phosphorylated tau 217 (p-tau217) – currently the strongest single blood marker of amyloid and tau pathology; basis of the first FDA-cleared blood tests.
- Phosphorylated tau 181 (p-tau181) – earlier-generation p-tau marker, often used to resolve p-tau217 "gray zone" results.
- Phosphorylated tau 231 (p-tau231) – rises very early, potentially in the preclinical stage.
- Total tau (t-tau) – general marker of neuronal injury, mainly in CSF.
- Glial fibrillary acidic protein (GFAP) – astrocyte activation marker; elevated early in amyloid-positive individuals.
- Neurofilament light chain (NfL) – nonspecific marker of axonal damage and neurodegeneration rate.
- Apolipoprotein E (ApoE) protein / ApoE4 isoform – the major genetic risk factor; the protein itself is measurable in plasma.
- Neurogranin – synaptic (postsynaptic) protein; elevated in CSF with synaptic loss.
- SNAP-25 – presynaptic protein marking synaptic degeneration.
- YKL-40 (chitinase-3-like protein 1) – glial/neuroinflammation marker.
- sTREM2 (soluble TREM2) – microglial activation marker.
- Brain-derived tau (BD-tau) – a newer blood marker of AD-specific neurodegeneration, more specific than NfL.
- Microtubule-binding region tau (MTBR-tau243) – tracks tau tangle burden and clinical stage.
- α-Synuclein and TDP-43 – co-pathology markers used to distinguish or identify mixed dementias alongside AD.
Licensing and accreditation
Our CLIA licensed, CAP accredited clinical laboratory is located at 2 Church Street South, B-05, New Haven CT 06519. For access to copies of our State and Federal license, please click on the links below:
State permits and licenses
- New York State Clinical Laboratory Permit (opens in a new tab)
- Connecticut Clinical Laboratory License (opens in a new tab)
- Maryland Medical Laboratory Permit (opens in a new tab)
- California Clinical and Public Health Laboratory License (opens in a new tab)
- Pennsylvania Clinical Laboratory Permit (opens in a new tab)